0 items
Your cart is empty.
99.2% On-Time Delivery
Tracked International Shipping
Refund Within 28 Days
Secure, Encrypted Checkout
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
99.2% On-Time Delivery
Tracked International Shipping
Refund Within 28 Days
Secure, Encrypted Checkout
$63.00
This product is available by prescription only
This product does not require a prescription
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
The product is delivered in powdered (lyophilized) form and must be properly reconstituted prior to research use.
SS-31 (Elamipretide) is a synthetic aromatic-cationic tetrapeptide — a four-amino acid sequence — characterized by its selective localization to the inner mitochondrial membrane (IMM). The peptide’s alternating aromatic and cationic residues enable electrostatic-driven mitochondrial uptake, concentrating SS-31 at the IMM independently of mitochondrial membrane potential. This targeting mechanism distinguishes SS-31 from membrane potential-dependent mitochondria-targeting compounds and makes it a relevant tool for studying IMM-localized pharmacological interactions under both healthy and depolarized mitochondrial conditions.
SS-31 is studied for its high-affinity interaction with cardiolipin — a dimeric phospholipid exclusive to the inner mitochondrial membrane that plays a structural and functional role in respiratory chain supercomplex organization, cytochrome c anchoring, and electron transport chain (ETC) efficiency. Researchers use SS-31 to examine how cardiolipin binding influences ETC complex activity marker expression, cytochrome c interaction dynamics, and mitochondrial membrane curvature parameters in controlled in-vitro membrane model systems and isolated mitochondria preparations.
SS-31 is studied for its effects on reactive oxygen species (ROS) production pathway dynamics and oxidative phosphorylation efficiency marker activity in mitochondrial experimental models. By interacting with cardiolipin and supporting respiratory supercomplex structural integrity, SS-31 enables researchers to examine downstream consequences on ETC electron leak marker activity, superoxide production pathway endpoint quantification, and ATP synthesis regulatory marker expression under baseline and oxidative stress-induced experimental conditions.
Novera supplies SS-31 10mg sourced from USA GMP-certified manufacturing facilities, verified to approximately 99% purity by independent third-party COA documentation. Each vial confirms the complete tetrapeptide sequence identity, purity grade, and batch-specific quality control data — providing research laboratories with consistent, pharmaceutical-grade material for advanced mitochondrial membrane pharmacology and bioenergetics research.
SS-31 10mg is suited for research teams investigating mitochondria-targeting peptide pharmacology, inner mitochondrial membrane interaction dynamics, and bioenergetics pathway marker quantification in controlled cell-based and preclinical models. Laboratories studying cardiolipin binding affinity characterization, reactive oxygen species (ROS) production pathway dynamics, or ATP synthesis regulatory marker activity will find this tetrapeptide relevant to mechanistic study designs. Research programs examining mitochondrial membrane integrity under stress-induced or age-associated experimental conditions, as well as cardioprotection and neuroprotection pathway mechanistic studies in preclinical cardiac and neuronal model systems, benefit from SS-31’s well-characterized targeting mechanism. Supplied by Novera from USA GMP-certified manufacturing facilities, each vial is COA-verified for purity and sequence identity to approximately 99%.
SS-31 supports in-vitro investigation of IMM-localized peptide interaction dynamics, cardiolipin binding affinity characterization, and respiratory supercomplex structural integrity parameter quantification in isolated mitochondria and cell-based experimental systems. Researchers examining the relationship between cardiolipin interaction and ETC complex I–IV activity marker expression use SS-31 as a primary reference compound for mitochondria-targeting peptide pharmacology study designs.
Laboratories studying mitochondria-associated oxidative stress pathway dynamics use SS-31 to examine ROS production endpoint quantification, superoxide dismutase pathway marker activity, and mitochondrial membrane lipid peroxidation assay outcomes under experimentally induced oxidative stress conditions. Multi-timepoint study designs allow systematic characterization of SS-31’s interaction with ROS production pathway markers across acute and chronic exposure experimental protocols.
SS-31 is studied in preclinical cardiac model systems for its effects on mitochondrial integrity marker dynamics during ischemia-reperfusion experimental conditions. Research quantifying cardiomyocyte mitochondrial membrane potential marker activity, cytochrome c release assay endpoints, and ATP synthesis pathway marker expression following ischemic challenge uses SS-31 to examine the molecular consequences of IMM-targeted cardiolipin interaction in cardiac cell mitochondrial stress models.
SS-31 is incorporated into preclinical neuronal model research examining mitochondrial bioenergetics pathway marker dynamics in neurodegenerative disease-associated experimental conditions. Laboratories investigating the relationship between IMM integrity, ETC efficiency marker activity, and neuronal ATP synthesis pathway endpoint expression under oxidative or metabolic stress conditions use SS-31 to characterize mitochondria-targeting peptide activity in neural cell mitochondrial model systems.
Reconstitute lyophilized SS-31 10mg with sterile bacteriostatic water using standard sterile laboratory technique. Reconstitution volume should be determined based on the target experimental working concentration specified by the study design. Research protocols typically employ experimental concentrations ranging from 0.25–5mg per administration depending on the cell model system, tissue target, and molecular endpoint under investigation. Use calibrated laboratory equipment for all preparation steps.
Store lyophilized peptide at 2–8°C in a cool, dark environment prior to reconstitution. SS-31 does not require cold-chain shipping and maintains stability during transit under standard shipping conditions. Following reconstitution, maintain refrigeration at 2–8°C; reconstituted peptide is stable for approximately 2–3 weeks under appropriate storage conditions. Protect from light throughout storage. Each vial supplied by Novera includes COA documentation and handling guidance.
Research protocols using SS-31 range from acute single-dose studies to extended multi-week observation designs depending on the mitochondrial pathway endpoints under investigation. Mitochondrial membrane integrity and bioenergetics marker studies typically span 4–12 weeks. Preclinical cardioprotection and neuroprotection pathway mechanistic studies may use acute ischemia-reperfusion challenge designs or chronic exposure protocols. Monitor ETC activity markers, ROS production pathway endpoints, ATP synthesis regulatory markers, and mitochondrial membrane integrity parameters at defined experimental timepoints throughout the observation period.
Novera Research delivers high-quality research peptides developed under strict manufacturing and quality-control standards. Each product is carefully synthesized, tested, and handled to ensure consistency, reliability, and transparency for advanced research applications.
High-purity, research-grade peptide synthesis
Analytical testing to verify quality and composition
Consistent batch-to-batch performance
Batch identification on every vial for traceability
Stored and shipped under controlled conditions
Research-grade selective synthetic pentapeptide formulated for experimental peptide interaction research in controlled laboratory settings.
Research-grade synthetic dual-agonist peptide formulated in 10mg quantity for dual-receptor mechanism studies and peptide-receptor interaction research in controlled laboratory environments.
Research-grade synthetic dual-agonist peptide formulated in higher-quantity 15mg format for extended dual-receptor pathway studies and institutional peptide research in controlled laboratory environments.
Research-grade dual-peptide formulation combining two synthetic peptides for streamlined laboratory peptide research protocols.
A synthetic GHRH analog studied for receptor binding kinetics, molecular interaction modeling, and pulsatile signaling pathway investigation in preclinical settings.
